- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Non-Alcoholic Steatohepatitis (NASH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacy accounting for % of the Non-Alcoholic Steatohepatitis (NASH) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Vitamin E & Pioglitazone segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Non-Alcoholic Steatohepatitis (NASH) Drugs include AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, and Genfit, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-Alcoholic Steatohepatitis (NASH) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market segment by Application, can be divided into
Hospital Pharmacy
Online Provider
Retail Pharmacy
Market segment by players, this report covers
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-Alcoholic Steatohepatitis (NASH) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-Alcoholic Steatohepatitis (NASH) Drugs, with revenue, gross margin and global market share of Non-Alcoholic Steatohepatitis (NASH) Drugs from 2019 to 2022.
Chapter 3, the Non-Alcoholic Steatohepatitis (NASH) Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-Alcoholic Steatohepatitis (NASH) Drugs market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-Alcoholic Steatohepatitis (NASH) Drugs research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Non-Alcoholic Steatohepatitis (NASH) Drugs
1.2 Classification of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type
1.2.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type in 2021
1.2.3 Vitamin E & Pioglitazone
1.2.4 Obeticholic Acid (OCA)
1.2.5 Elafibranor
1.2.6 Selonsertib & Cenicriviroc
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Application
1.3.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size & Forecast
1.5 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast by Region
1.5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region, (2017-2022)
1.5.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Prospect (2017-2028)
1.5.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Prospect (2017-2028)
1.5.6 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
1.6.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
1.6.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.1.4 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Conatus Pharmaceuticals
2.2.1 Conatus Pharmaceuticals Details
2.2.2 Conatus Pharmaceuticals Major Business
2.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.2.4 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Conatus Pharmaceuticals Recent Developments and Future Plans
2.3 Enzo Biochem
2.3.1 Enzo Biochem Details
2.3.2 Enzo Biochem Major Business
2.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Enzo Biochem Recent Developments and Future Plans
2.4 Galmed Pharmaceuticals
2.4.1 Galmed Pharmaceuticals Details
2.4.2 Galmed Pharmaceuticals Major Business
2.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.4.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Galmed Pharmaceuticals Recent Developments and Future Plans
2.5 Genfit
2.5.1 Genfit Details
2.5.2 Genfit Major Business
2.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.5.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Genfit Recent Developments and Future Plans
2.6 Gilead
2.6.1 Gilead Details
2.6.2 Gilead Major Business
2.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.6.4 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Gilead Recent Developments and Future Plans
2.7 Horizon Pharma
2.7.1 Horizon Pharma Details
2.7.2 Horizon Pharma Major Business
2.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.7.4 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Horizon Pharma Recent Developments and Future Plans
2.8 Immuron
2.8.1 Immuron Details
2.8.2 Immuron Major Business
2.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.8.4 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Immuron Recent Developments and Future Plans
2.9 Intercept Pharmaceuticals
2.9.1 Intercept Pharmaceuticals Details
2.9.2 Intercept Pharmaceuticals Major Business
2.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.9.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Intercept Pharmaceuticals Recent Developments and Future Plans
2.10 Novo Nordisk
2.10.1 Novo Nordisk Details
2.10.2 Novo Nordisk Major Business
2.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
2.10.4 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Novo Nordisk Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share in 2021
3.2.2 Top 10 Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Players Head Office, Products and Services Provided
3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Mergers & Acquisitions
3.5 Non-Alcoholic Steatohepatitis (NASH) Drugs New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Market Share by Type (2017-2022)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2017-2022)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2028)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2028)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2028)
6.3.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2028)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2028)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2028)
7.3.2 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
7.3.3 France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
7.3.5 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
7.3.6 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Region (2017-2028)
8.3.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8.3.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8.3.5 India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
8.3.7 Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2028)
9.2 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2028)
9.3 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
9.3.1 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2028)
9.3.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country
10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2028)
10.3.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
10.3.4 UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Region (2023-2028)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 9. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Conatus Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Conatus Pharmaceuticals Major Business
Table 12. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 13. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Enzo Biochem Corporate Information, Head Office, and Major Competitors
Table 15. Enzo Biochem Major Business
Table 16. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 17. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Galmed Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 19. Galmed Pharmaceuticals Major Business
Table 20. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 21. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Genfit Corporate Information, Head Office, and Major Competitors
Table 23. Genfit Major Business
Table 24. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 25. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Gilead Corporate Information, Head Office, and Major Competitors
Table 27. Gilead Major Business
Table 28. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 29. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Horizon Pharma Corporate Information, Head Office, and Major Competitors
Table 31. Horizon Pharma Major Business
Table 32. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 33. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Immuron Corporate Information, Head Office, and Major Competitors
Table 35. Immuron Major Business
Table 36. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 37. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Intercept Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 39. Intercept Pharmaceuticals Major Business
Table 40. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 41. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 43. Novo Nordisk Major Business
Table 44. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 45. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Non-Alcoholic Steatohepatitis (NASH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Non-Alcoholic Steatohepatitis (NASH) Drugs Players Head Office, Products and Services Provided
Table 50. Non-Alcoholic Steatohepatitis (NASH) Drugs Mergers & Acquisitions in the Past Five Years
Table 51. Non-Alcoholic Steatohepatitis (NASH) Drugs New Entrants and Expansion Plans
Table 52. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) by Type (2017-2022)
Table 53. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Type (2017-2022)
Table 54. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Forecast by Type (2023-2028)
Table 55. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022)
Table 56. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Forecast by Application (2023-2028)
Table 57. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Picture
Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type in 2021
Figure 3. Vitamin E & Pioglitazone
Figure 4. Obeticholic Acid (OCA)
Figure 5. Elafibranor
Figure 6. Selonsertib & Cenicriviroc
Figure 7. Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application in 2021
Figure 8. Hospital Pharmacy Picture
Figure 9. Online Provider Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Region (2017-2028)
Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Region in 2021
Figure 15. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
Figure 21. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
Figure 22. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends
Figure 23. AstraZeneca Recent Developments and Future Plans
Figure 24. Conatus Pharmaceuticals Recent Developments and Future Plans
Figure 25. Enzo Biochem Recent Developments and Future Plans
Figure 26. Galmed Pharmaceuticals Recent Developments and Future Plans
Figure 27. Genfit Recent Developments and Future Plans
Figure 28. Gilead Recent Developments and Future Plans
Figure 29. Horizon Pharma Recent Developments and Future Plans
Figure 30. Immuron Recent Developments and Future Plans
Figure 31. Intercept Pharmaceuticals Recent Developments and Future Plans
Figure 32. Novo Nordisk Recent Developments and Future Plans
Figure 33. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players in 2021
Figure 34. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share in 2021
Figure 36. Global Top 10 Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Type in 2021
Figure 39. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Type (2023-2028)
Figure 40. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application in 2021
Figure 41. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Application (2023-2028)
Figure 42. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2017-2028)
Figure 43. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2017-2028)
Figure 44. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Country (2017-2028)
Figure 45. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2017-2028)
Figure 49. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2017-2028)
Figure 50. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Country (2017-2028)
Figure 51. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Region (2017-2028)
Figure 59. China Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2017-2028)
Figure 66. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2017-2028)
Figure 67. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
